HLB (028300) wrapped up the week with a gain in the last trading day, drawing investors' attention to next week's share price movement.

On the 4th, HLB finished trading on the KOSDAQ regular session at 33,750 won, up 950 won (2.90%) from the previous trading day. As the stock held onto positive territory heading into the weekend, whether buying interest will continue next week is a key point of interest.

Notably, HLB has been a stock highly sensitive to news related to new drug development and the U.S. Food and Drug Administration (FDA), so investor attention is expected to remain on related issues alongside the overall market direction.

◆ Rivoceranib FDA Resubmission Emerges as Key Variable for Share Price

HLB's liver cancer drug rivoceranib previously received a Complete Response Letter (CRL) in the FDA approval process in July. The company subsequently announced that the FDA inspection of the rivoceranib active pharmaceutical ingredient manufacturing facility was classified as 'Voluntary Action Indicated (VAI).'

Recently, preparations for the FDA approval resubmission of rivoceranib combination therapy has become a topic of market interest.

Accordingly, HLB's share price going forward may be influenced not only by the KOSDAQ index movement but also by investment sentiment in the pharmaceutical and biotech sectors and follow-up news related to the new drug.

Whether HLB will attempt a further rebound based on the strength seen on the 4th or whether volatility will expand again remains to be seen, with attention focused on HLB's movement from the first trading day of next week.

[※ This article is for informational purposes only as reference material for investment decisions and is not intended to recommend investment in any specific stock.]